Scientific deep-dive
Why GLP-1 Drugs Make You Tired, and What Nobody Has Studied
Fatigue runs 11% against 5% on placebo, and rises with dose: 5% to 9% to 11%. That dose-response hints that the drug itself contributes, although higher doses also take off more weight, and almost nothing else has been studied.
Fatigue is in the label, it is roughly twice as common as on placebo, and it gets more common as the dose goes up: 5% on placebo, 9% at 2.4 mg, 11% at 7.2 mg.[1] That dose-response is the most useful thing anyone can tell you about it, because it is the strongest available hint that the drug itself contributes, although higher doses also take off more weight. Beyond that, almost nobody has studied it, and what follows is reasoning rather than evidence.
What the label counted
In the main adult weight-management trials, covering 2,116 people on semaglutide 2.4 mg, fatigue was reported by 11% against 5% on placebo.[1] It sits in the adverse reactions table alongside nausea and headache, in the common, generally self-limiting group, and not in any warning section.
A separate table covering the 7.2 mg dose reports the three-way comparison: 5% on placebo, 9% at 2.4 mg, 11% at 7.2 mg.[1]
More drug, more tiredness. That pattern points toward the drug itself, and it is the closest thing on the label to the brain fog people describe.
A dose-response relationship is one of the classic arguments for causation. If fatigue were simply a consequence of eating less or losing weight, you would expect it to track weight loss rather than milligrams. Higher doses do produce more weight loss, but the stepwise pattern across three arms is at least suggestive that the drug contributes directly.
What is probably going on
This section is inference. There is no trial that took people with fatigue on a GLP-1, tested an explanation, and reported a result. Instead, several well-established mechanisms plausibly apply, each with its own evidence base elsewhere.
- You are eating substantially less. A large calorie deficit produces tiredness in anyone, by any method. This is the most likely single contributor and the least specific to these drugs.
- Dehydration. Nausea, vomiting and diarrhea all reduce fluid intake and increase losses, and dehydration causes fatigue well before it causes anything worse. It is also the mechanism behind the acute kidney injury the label warns about (see kidneys).
- Under-eating protein specifically. Appetite suppression tends to cut protein first, because protein-rich foods are the ones that feel heaviest. Our protein calculator works a target.
- Losing lean tissue. Roughly a quarter to a third of weight lost is lean mass, which is comparable to what lifestyle programs cost (the lean mass article covers it). Less muscle means the same task takes more of what you have. Whether it also causes aches has never been tested; what the trials counted for joint and back pain sets out what is known.
- Low blood sugar, if you take something else for it. Fatigue is a hypoglycemia symptom, and the risk lives with insulin and sulfonylureas rather than the GLP-1. The low blood sugar article sets that out.
What is worth checking rather than assuming
Fatigue is the least specific symptom in medicine, and starting a new drug is exactly when a different cause gets attributed to it. The things worth ruling out are cheap to check and common in this population.
- Thyroid function, which is a routine test and a routine cause.
- Iron and B12. Eating much less for months carries a risk of falling short on micronutrients,[2] and a shortfall in either one causes exactly this.
- Sleep apnea, which is common in this population and improves with weight loss (see sleep apnea).
- Mood, because low energy and low mood are hard to tell apart from the inside.
None of that is a reason to assume the drug is innocent. It is a reason not to assume it is guilty, which is what happens when a new medicine gets blamed for everything that follows it. The same logic applies to a drop in sex drive on a GLP-1.
When it is not ordinary tiredness
Frequently Asked Questions
References
- 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 6.1 Adverse Reactions: fatigue 11% vs 5% placebo (2.4 mg, N=2,116) and 5%/9%/11% across placebo, 2.4 mg and 7.2 mg (N=1,311) (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 2.Kwaśny A, Słoma-Krześlak M, Kostelecki G, et al. Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics Adv Clin Exp Med. 2026. PMID: 42823936.
Compare the sellers
Related research
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off
Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.
10 min read
GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days
Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.
7 min read
GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk
A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.
6 min read
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.
7 min read
Ozempic and Gastroparesis: How Real Is “Stomach Paralysis”?
GLP-1 users are diagnosed with gastroparesis more often, about 6.5 per 1,000 a year on semaglutide against 2.1 on another weight drug. What the Ozempic and Mounjaro labels added and when, whether it reverses, and where MDL 3094 stands.
11 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Wellorithm
From $247/mo
Get started →Embody
From $79/mo
Get started →Collective
From $59/mo + membership
Get started →